US FDA Manufacturing Enforcement In Brief: Recent Warning Letters And Import Alerts
Executive Summary
Recent US FDA drug GMP warning letters featured findings of lax contamination controls and data integrity issues at firms in China, India, Japan, Illinois and East Texas. Meanwhile, FDA hit six plants in India and China with drug GMP import alerts.
You may also be interested in...
OTC Recalls: Children's Allergy Tablets, Eye Care Products
Standard Homeopathic's recent recall of its Hyland’s teething tablets was designated class I, indicating a reasonable probability of serious adverse health consequences or death, FDA notes in May 31 update to its recalls database.
OTC Recalls: Children's Allergy Tablets, Eye Care Products
Standard Homeopathic's recent recall of its Hyland’s teething tablets was designated class I, indicating a reasonable probability of serious adverse health consequences or death, FDA notes in May 31 update to its recalls database.
Enforcement Log, Dateline 09.30.16: Pan Drugs, Zhejiang Hisoar, Wockhardt, Zhejiang Bangli, Pharmaceutics International
Pan Drugs, Zhejiang Hisoar hit with data integrity warning letters; Wockhardt, Zhejiang Bangli and three others lose US market access; Pharmaceutics International's EU access in jeopardy.